alexa Erlotinib Nanosuspension: In Vitro Anti-cancer Study Using Colon Cancer Cell Line
ISSN: 2376-0419

Journal of Pharmaceutical Care & Health Systems
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

10TH Asia-Pacific Pharma Congress
May 08-10, 2017 Singapore

L Panayappan, B Dinesh kumar and K Jayaprakash
St. James College of Pharmaceutical Sciences, India
Posters & Accepted Abstracts: J Pharma Care Health Sys
DOI: 10.4172/2376-0419-C1-021
Erlotinib is used for the treatment of lung and pancreatic cancer. The clinical usage of erlotinib is limited due to its poor solubility and dissolution rate. The objective of the research work is to formulate erlotinib nanosuspension with improved solubility and dissolution rate and investigation of its anticancer activity against colon cancer cell line (HCT 116). Erlotinib nanosuspension (ENS) was prepared by high pressure homogenization method. Characterization of ENS was performed using zeta potential analysis and particle size termination by SEM analysis. ENS was subjected to solubility study as well as stability study. Further, ENS was subjected to in vitro anti-cancer activity against colon cancer cell line. The study results indicated that the prepared ENS by high pressure homogenization method include several advantages, such as suitable for poorly water soluble drugs/ herbal drugs and suitable for large scale production. Particle size of ENS showed range from ~5 to 26 nm. Zeta potential value of formulated nanosuspension was obtained as 3.16 mv. Solubility study indicated that formulated ENS enhanced the solubility of the erlotinib. Stability study showed ENS was stable in room temperature and cold temperature. ENS exhibited significant anti-cancer activity against HCT-116 Cell line at dose dependent manner. The study concluded that high pressure homogenization method could be suitable to improve the solubility of erlotinib and ENS exhibited effective anti-cancer activity against colon cancer cell line.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version